Pan European Networks - Horizon 2020 - page 201

ervical cancer (CC) is the second most common cause of
cancer-related deaths in women worldwide, and sexual
transmission of the human papilloma virus (HPV) is
commonly accepted as its major trigger factor.While preventive
anti-HPV vaccination is expected to impact incidence rates more
than 20 years from now, when the first vaccinated adolescents will
reach the age of peak incidence (35-50) of CC, many women are
not vaccinated and remain at risk.
The RAIDs consortium proposes a rational approach towards
building intelligent new treatment designs based on the
understanding of specific wiring errors in tumour cell signalling. It
aims for a comprehensive analysis of the tumour and in parallel
studies the impact of tumour cell molecular abnormalities on the
tumour micro-environment.
RAIDs aims to design better precision medicine tools as well as to
improve therapeutic vaccine strategies against cancer through
preclinical and clinical studies. At the core of RAIDs is BioRAIDs, a
prospective multi-centre European clinical study with extensive
biobanking, allowing for molecular profiling and applying high
standards for quality control of biological and clinical data.
Genetic mutations (SeqOmics, Hungary), proteomic alteration (a
translational platform of Institut Curie (IC), Paris) and their
influence on the tumour micro-environment (Netherlands Cancer
Institute (NKI), Amsterdam) of cervical cancers in seven EU
countries are being analysed.
BioRAIDs is one of the first prospective biobanking trials to date.
The main clinical trial support structures are based at the promoter
site (IC, Paris), with sponsorship delegations to the HCTC
(Hannover), Hannover Medical School, ECRIN (the European
Clinical Research Infrastructures Network (Paris)) and the NKI
(Amsterdam). The main challenges towards the initiation of this
large clinical study have been: 1) lacking harmonisation in
regulatory requirements across Europe; 2) variable levels of
experience with a) biobanking, b) clinical trial conduct; and 3)
budgetary issues. BioRAIDs is actively including patients today in
six EU countries, and real-time analysis is on-going.
Government authorities, parliamentary representatives and health
advocates should be aware that the dimension of this public health
problem in some EU countries – with only recently established
screening practices and virtually no clinical trial experience or
infrastructure – requires special attention as regards health
statistics, in contrast to richer EU countries with relatively low
incidence rates where it represents an orphan disease with little
interest by industry and virtually no funding for clinical research.
RAIDs results will be priceless in identifying a set of
stratification criteria that will help in the near future to better
orient patients towards personalised treatment strategies, as
well as to improved vaccine strategies.
Drug sensitivity screenings on CC cell lines already show highly
interesting findings that may suggest new alleys for treatment
proposals (INSERM, France) as a function of specific molecular
alterations. Sophisticated CC animal modelling demonstrated a
synergy between a therapeutic HPV vaccine with radiotherapy
(Gustave Roussy). A first-in-Man DNA vaccine trial, currently on-
going at the NKI, is accruing well. In patients, the evolution of
documented tumour genetic changes during the course of
treatment is assessed using targeted sequencing in liquid
biopsies (ERASMUS, Rotterdam). SeqOmics (Hungary) plans to
develop a molecular profiling platform for patient tumours in
neighbouring countries.
This project has received funding from the European Union’s
Seventh Framework Programme for research, technological
development and demonstration under grant agreement
No 304810.
Suzy Scholl
MD – MRCOG – HDR Co-ordinator of RAIDs
Senior Medical Oncologist at Institut Curie
te l :
+33 1 44 32 46 87
RAIDs is an EU-funded consortium studying cervical cancer as a model system
for precision medicine diagnostics, therapeutic precision medicine and
vaccine development
Molecular diagnosis and treatment
H O R I Z O N 2 0 2 0 P R O J E C T S : P O R TA L
1...,191,192,193,194,195,196,197,198,199,200 202,203,204,205,206,207,208,209,210,211,...244
Powered by FlippingBook